George is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT). He is Director of the U.S. Department of Energy Technology Center and Director of the National Institutes of Health Center of Excellence in Genomic Science. He has received numerous awards including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute and election to the National Academy of Sciences and Engineering.

George leads Synthetic Biology at the Wyss Institute and is widely recognized for his innovative contributions to genomic science and his many pioneering contributions to chemistry and biomedicine. In 1984, he developed the first direct genomic sequencing method, which resulted in the first genome sequence (the human pathogen, H. pylori). He helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005.

Dr. Nir Barzilai serves as director of the Institute for Aging Research at the Albert Einstein College of Medicine. In addition, he is a founder and board member of CohBar Inc. Listed on the Russel 2000 Index, it develops therapeutics based on mitochondrial-derived peptides. He is a renowned expert and scientist in the study of the biology and genetics of aging.

He is also a founder and a Medical Consultant to Lifebiosciences, targeting therapeutics against the hallmark of aging. He is leading the TAME (Targeting Aging with MEtformin) multi-central study to show that aging can be a target in humans in support of changing the FDA indication that is relevant to targeting aging.

Dr. Barzilai is the recipient of many awards including the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity Award. His work has been profiled by outlets such as the New York Times, BBC, PBS, and National Geographic. He received his MD from Technion-Israel Institute of Technology.

Dr. Aubrey de Grey is an English author and biomedical gerontologist. He is the author of The Mitochondrial Free Radical Theory of Aging and co-author of Ending Aging. His research interests encompass the characterisation of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage.

Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Ageing Association, and sits on the editorial and scientific advisory boards of numerous journals and organisations. He is a highly sought-after speaker who gives talks at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.

Dr. Brian Kennedy is internationally recognized for his research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of detecting, delaying, preventing and treating human aging and associated diseases. He is a Distinguished Professor in Biochemistry and Physiology at the Yong Loo Lin School of Medicine at National University Singapore and serves as Director of (1) the Centre for Healthy Longevity at the National University Health System, (2) the Healthy Longevity Translational Research Program, and (3) the NUS Bia-Echo Asia Centre for Reproductive Longevity and Equality.

Dr. Kennedy has adjunct appointments at the Department of Biochemistry at the University of Washington, where he was a faculty member from 2001 to 2010. In addition, Dr. Kennedy is also actively involved with a number of Biotechnology companies. In addition, Dr. Kennedy serves as a Co-Editor-In-Chief at Aging Cell.

Charles Brenner is a biochemist and leading expert on nicotinamide adenine dinucleotide (NAD), the central catalyst of metabolism. He discovered the nicotinamide riboside (NR) kinase pathway and the technologies that led to development of NR as an NAD-booster. He also developed quantitative targeted NAD metabolomics, which allowed him and others to determine that the NAD system is disturbed in a wide variety of diseases and conditions of metabolic stress including obesity, alcoholism, time zone disruption, DNA damage, reactive oxygen species stress, noise-induced hearing loss, central and peripheral neurodegeneration, infection and inflammation, heart failure, postpartum, and some malignancies. Dr. Brenner’s work has led to more than 50 registered clinical trials for NR and global interest in NR for healthy aging.

Dr. Brenner is the winner of numerous awards in biochemistry and nutrition science. In addition to running a highly productive research group at City of Hope, he serves as chief scientific advisor for ChromaDex and Juvenis and as a co-founder of Alphina Therapeutics.

Dr. Eric Verdin is the President and Chief Executive Officer of the Buck Institute for Research on Ageing. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Gladstone Institute at the University of California San Francisco (UCSF). Dr. Verdin is currently adjunct Professor of Medicine at UCSF and Adjunct Professor at the University of Southern California (USC).​

Dr. Verdin studies how metabolism, diet, and small molecules impact epigenetic regulatory mechanisms, and thereby the ageing process and its associated diseases. He is a highly cited scientist (top 1 percent) and has been recognized for his research with multiple awards including a fellowship from the American Association for the Advancement of Science, election to the American Society for Clinical Investigation, the Association of American Physicians, and Belgium’s Royal Academy of Medicine.

Christian Angermayer is a serial entrepreneur, investor and visionary who builds and invests in companies that are shaping the Next Human Agenda: a future in which technology empowers people to live longer, healthier, and happier lives.

Christian’s family office and private investment company, Apeiron Investment Group has more than USD 3.5 billion under management and 60 people across five international locations. Apeiron focuses on Life Sciences, FinTech & Crypto, Future Tech and Entertainment, Leisure & Hospitality. Over the past 20 years, Christian has founded three unicorns and has been the lead investor in four unicorns and two decacorns. His current areas of focus include: psychedelics and mental health, longevity, crypto and future tech.

Michael Greve is the founder of the Forever Healthy Foundation and owner of Kizoo Technology Ventures.

With his own team, he produces scientific papers that can be thought of as a screenshot of current world knowledge on a topic - each paper based on about 2000 abstracts and 150 studies. He publishes them in a database on his website, freely accessible to anyone at any time, comprehensively transformed into practical advice.

He has turned himself into the leading global figure of a new approach to longevity: he talks about rejuvenation, the preservation and restoration of youth. He talks about viewing the process of aging as a treatable disease, not an inescapable fate. All this not with the goal of eternal life, but of prolonging the healthy life span as much as possible.

Alex Zhavoronkov is the CEO of Insilico Medicine, a Rockville-based leader in the next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research.

He set up the R&D centers in 6 countries including the United Kingdom, Korea, Russia, Hong Kong and Taiwan and launched multiple B2B and B2C research platforms including Young.AI. Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies, NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and Diversity.AI initiative.

He is the co-organizer of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at the Basel Life/EMBO, one of Europe's largest industry events in drug discovery. Dr. Zhavoronkov is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

Dr. Wei-Wu He has been serving as Executive Chairman of Human Longevity Inc. since July 2019. Dr. He is currently the Chairman of CASI Pharmaceuticals, Inc., OriGene, Juventa, Sophonix and founder of Genetron Health; Dr. He also is the Founder and General Partner of Emerging Technology Partners, LLC (ETP), a life sciences focused venture fund established in 2000.

In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author of more than 50 research publications and inventor of over 32 issued patents. Dr. Wei-Wu He received his PhD in Molecular Biology from Baylor College of Medicine and received an MBA degree from the Wharton School.

Amy Killen, MD is a leading regenerative physician with a focus on sexual optimization as a
driver for health and longevity. In her Utah-based practice she combines stem cell injections with photobiomodulation, shockwave therapy, body-identical hormones,
nutritional supplements, peptides and old-fashioned healthy lifestyle to give patients unparalleled synergistic regenerative effects for sexual systems.

Dr. Killen is also the founder and CEO of the Human Optimization Project, a
longevity-focused nutritional supplement and education platform that makes staying on
top of current trends in aging prevention easy and fun, and she is on the core team of Reputable, a decentralized science platform that incentivizes betterment experiments and aggregates N of 1 data into actionable insights.

She practiced emergency medicine for ten years before transitioning to longevity and
regenerative medicine. She now divides her time between clinical work, international
speaking engagements, educational content creation, her entrepreneurial endeavors and her family of five.

José Luis Cordeiro Mateo is a Venezuelan-Spanish engineer, economist, futurist, and transhumanist, who has worked on areas including economic development, international relations, Latin America, the European Union, monetary policy, comparison of constitutions, energy trends, cryonics, and life extension. Books he has written include The Great Taboo, Constitutions Around the World: A Comparative View from Latin America, and (in Spanish) El Desafio Latinoamericano ("The Latin American challenge"), and La Muerte de la Muerte ("The death of death").

Cordeiro is an international fellow of the World Academy of Art and Science (WAAS), executive director of the Ibero-American Futurists Network, Venezuela Node Chair of The Millennium Project, vice chair of Humanity Plus, and former director of the Club of Rome (Venezuela Chapter), the World Transhumanist Association, and the Extropy Institute.

In the 2019 European Parliament election in Spain, Cordeiro ran for MEP as the candidate for the Movimiento Independiente Euro Latino, promoting the representation of Latin Americans in Spain and Europe and promoting science and research to build better societies.

Eric oversees BIOAGE’s clinical and computational efforts to bring new therapeutics to the clinic that target fundamental mechanisms of aging. Eric was previously an assistant professor at the University of Toronto, where his research focused on biomarker discovery and characterization in high-dimensional datasets from human cohorts. He completed an HBSc in artificial intelligence, MD, clinical training in pathology, and a research fellowship in computational biology and molecular epidemiology at the University of Toronto, where he held a Canada Graduate Scholarship from the CIHR, and was subsequently a CIHR research fellow. He has published over 15 papers in the areas of molecular biomarker discovery, pharmacogenomics, aging, and diagnostic medicine. Eric is a licentiate of the Medical Council of Canada, a fellow of the Royal College of Physicians and Surgeons of Canada, holds a specialty designation in pathology, and previously practiced medicine at Mount Sinai Hospital in Toronto.

Martin Jensen is a CSO at Gordian Biotechnology. He is also the producer of the program at Impetus Grants where he ran the first round of Impetus Grants. His focus is on developing technologies to interrogate the full network of ageing processes inside living organisms. This includes multiplexed measurement of complex states, interpretable perturbations, and context-aware data models.

Previously, he was an academic working on a range of cellular mechanisms involved in ageing: mitochondrial function, NAD metabolism, DNA damage signalling and other stress responses.

As Market Head of the international location Gstaad and Member of the Management Committee Private Banking Region Mittelland, Manuel Blanco runs a team of banking industry professionals with focus onto entrepreneurs, impact investors, global families and wealthy individuals.

In his 28 years of industry experience he was responsible for the Executive & Entrepreneurs Desk for Germany International & Domestic within the UHNW Wealth Management International Division. Later he became responsible for the Business Development & Growth of the Spanish market. By collaborating cross-divisional he could gain enhanced investment management skills and offer Investment Banking deal-flow to Semi-Institutional clients with a holistic advisory approach. During this time he was in management positions as well as specialist position. Manuel Blanco graduated with a Master Degree in Science of Wealth Management of the University of Rochester (NY) and with
a Master in Advanced Science of Finance of the University of Bern (Switzerland) in 2018.

As a pan-european person he owns a Swiss and a Spanish citizenship. Manuel Blanco is married, he is father of 3 children and he lives in Switzerland. As Founder of the Impact Summit Gstaad Association he enables Investors to access globally ESG conform Investments. He is a board member of the Official Spanish-Swiss Chamber of Commerce and of a local Swiss soccer club and he is a member of the Swiss German Parliament Friendship-Club. In his leisure time he is interested in geo-politics, ESG, soccer, skiing and music.

Simone is CEO of Clinique La Prairie, one of the most iconic Swiss brands, where he is driving its international development and its diversification strategy, with the mission of creating a global player able to help people live a longer, healthier and better life.

Simone is CEO and co-founder of Clinique La Prairie Holistic Health, a leading ultraluxury company in “Longevity Supplements”.

Simone serves on the board of various companies in the field of Cosmetics, Health and Genetics. He writes and teaches (in business school and universities) about marketing, brand building, strategy, and organisational subjects.

Olga's career journey started with a nutritionist degree and led her to pursue her passion for all research and sciences related to holistic health and wellness. She joined Clinique La Prairie in 2018, focusing on fostering the innovative approach of longevity, a field that is shaped by continuous overwhelming scientific findings. She describes her mission as a challenging yet inspiring task, as well as an important responsibility. Her specific areas of expertise include weight management, detoxification approach, metabolic health, revitalization treatments and nutraceuticals. Olga explores the potential of precision medicine, nutrition and individualized plans combined with cutting-edge longevity technologies, advanced treatments, and innovative clinical approach, to continuously enhance Clinique La Prairie’s programs in collaboration with the clinic’s experts.

Miri Polachek is an entrepreneurial executive and investor with over 25 years’ experience in the healthcare industry. She is currently General Partner at a newly formed venture capital fund investing in rejuvenation medicine. Until recently, Miri served as CEO of Joy Ventures, a venture builder and fund in the consumer mental health and wellbeing domain.

Miri co-founded and led Israel Brain Technologies, which served as a hub and catalyst for braintech innovation and commercialization, including the world’s first braintech startup accelerator. Miri has also held financial management positions in leading global healthcare companies including Pfizer and Teva, and was VP Finance at IntegraMed. She holds an MA in Health Economics from Boston University and an MBA from New York University.

Sebastian has more than 10 years of experience in the life science industry, from applied and basic research to venture capital investments and portfolio management. He joined the Apollo Health Ventures investment team as a partner in August 2022 and focuses on venture investing and company building.

Prior to that, Sebastian was an investment professional at coparion, a venture capital firm investing in young German technology startups. In this role he led the life science related investment activities at coparion. His portfolio consisted of pharmaceutical and medical technology companies in various development stages (from concept to clinic), working on different indications and exploiting diverse therapeutic entities. Before joining coparion, Sebastian started his VC career as an analyst intern at Gimv, a European investment company.

Sebastian holds a PhD in molecular biology from the International Max Planck Research School for Molecular Life Sciences (IMPRS-LS) Munich and the LMU Munich Medical Faculty.

Dr. Emil Kendziorra is a founder and CEO at Tomorrow Biostasis GmbH based in Berlin, Germany, and President of the Board at European Biostasis Foundation, a non-profit research foundation in Switzerland.

He has a strong background in medicine, cancer research, and entrepreneurship. He has been CEO of multiple tech and medical companies, most recently as a Founder and CEO of Medlanes (Exit to ZAVA) and onFeedback (Exit to QuestionPro).

Emil graduated summa cum laude in medicine from the University Medical Center Göttingen - one of the leading medical schools in Germany - with a doctoral degree in translational cancer research. He’s a regular keynote speaker on future of healthcare policy, the overlap of healthcare, science, and technology as well as an advisor to insurances, hospital chains, and pharmaceutical companies on digitalization topics.

Furthermore, he’s a mentor to a wide range of startups and (rarely) an early-stage angel investor.

Emil has decided to dedicate the next decades of his life to Medical Biostasis and cryomedicine.

After starting his first company at the age of 15, over the past 20 years Rob has accumulated a broad range of experience in the fields of entrepreneurship, strategic consulting and international management.

After consulting some of the leading health and pharmaceutical companies during his time with one of the BIG4 professional services firms, he served as Head of International Marketing for the leading Swiss retail group with over 25 individual companies, co-founded a software company and was CEO of two renowned companies in the field of International Health Insurance and Health Management.

As a longevity enthusiast and life-long tech geek, he believes the more you know about your body, the more you can improve your health and wellbeing, and is developing solutions and programs to help people do exactly that. Rob also holds a doctorate in Public Healthcare Management.

Elisabeth Roider is Harvard-and Swiss-trained, internationally renowned physician scientist. As a Partner & Chief Scientific and Medical Officer at Maximon she is dedicated to bring the field of longevity to the next level.

As a physician-scientist, she is working at the University Hospital of Basel and the Harvard Medical School. Her multidisciplinary team includes clinicians and clinical trial specialists, biologists, chemists, machine learning specialists, mathematicians, statisticians, and epidemiologists, allowing a bench-to-bedside approach to solve complex, medical questions in the most efficient way. Her work has resulted in various high-impact publications, patents and awards.

Driven by the mission to identify and solve the most relevant medical and public health problems, Elisabeth most recently joined Maximon as a Partner & Chief Scientific and Medical Officer. Here she aims to support scientists and physicians in transforming true innovation into solid solutions and products, helping patients and consumers to achieve a better, healthier and finally longer life.

Sophie has received an MSc in Food Science, Nutrition & Health from ETH Zurich. She combined this strong scientific background, years of industry knowledge working at a leading FMCG company, and her entrepreneurial mindset to co-found Avea. Her goal is to bring innovative and effective supplements with a focus on ingredient synergies to the market.

Sophie’s passion for helping people achieve optimal health and well-being is what makes her thrive in her role as Chief Product Officer of Avea. Her personal interest in longevity began as she researched specific anti-ageing molecules during her studies and has since been on an active search to optimize her and her loved ones health and wellness routines.

Her scientific background and interest in health supplements and rituals allow Sophie to do the necessary scientific research while maintaining a consumer-focused approach when creating Avea’s unique formulations.

Jörg is a serial investor and entrepreneur who started his first company right after college. After only 3 years he successfully excited his first company and since then he is passionate about building companies that make an impact. Jörg established, amongst other companies, a leading European IT asset management strategy consultancy which he sold to one of the BIG4 where he then served 4 more years as global lead partner. Jörg has so far invested in more than 25 start-ups as well as midsized companies. With 9 out of 10 start-ups successful (including 2 IPOs and 1 Unicorn) Joerg has shown a good hand in building and investing in companies. He is a member of selected Advisory Boards and teaches “Entrepreneurship and Innovation” at a leading private university in Germany.

Robin Lauber is an entrepreneur at heart and has built several successful companies across various verticals. His family office has a core focus on investing in Swiss real estate and venture capital. He is passionate about investments in breakthrough technologies and teams up with some of the best partners, founders, and investors across Europe to make bold visions a reality. Infinitas capital also manages Korify Capital, a global co-investment fund series
investing in the most exclusive venture opportunities along with tier-1 VCs.

Prof. Evelyne Bischof is a Chief Physician Associate of Internal Medicine at University Hospital Renji of Jiaotong University Shanghai and concierge longevity physician for executive longevity patients.

Her research focus is oncology and longevity medicine, Artificial Intelligence (AI) and digital health, precision medicine, biogerontology, and geronto-oncology. She published over 80 peer-reviewed papers, is a frequent speaker at scientific and medical conferences in Asia and Europe.

Long term member of various medical societies, e.g. European Federation of Internal Medicine, World Academy of Medical Sciences, Swiss Society of Internal Medicine etc. Evelyne spent a decade practicing medicine, lecturing at medical schools and performing clinical and translational research in New York, Shanghai and Basel, with extensive experience in scientific research and clinical practice.

Dr. sc. med. Elena Gross is the founder and CEO of KetoSwiss, a Swiss biotech startup, winner of this year's Top 100 Swiss startup public award. KetoSwiss develops highly potent therapeutic ketones for neurological disease prevention.

Elena started her career in academia. She used to be a chronic migraine patient and due to the lack of tolerable and efficacious treatment options, she pursued an MSc in Neuroscience at the University of Oxford. There, she discovered ketone bodies & their potential therapeutic use in neurological disease, which changed her life.

Entrepreneurial in spirit, she is the inventor of two patents. She also initiated & funded the first ever clinical trial using exogenous ketone body salts in the world in her PhD at the University of Basel and University of Harvard Medical School.

Guenther is a Partner at PwC Zurich and Leader of PwC Legal Switzerland. He is also one of seven members of PwC’s Global Legal Leadership Team and PwC Legal’s Global LegalTech Leader.

He is the author of 10 books mostly on investment law and regulation but also of “Making Money out of Technology”, “Uptake Revisited: How Innovative Products Succeed in International Markets” and “New Suits. Appetite for Disruption in the Legal World”. Guenther is also the host of the educational video series „Appetite for Disruption“, the founder of global technology enthusiasts movement Disruption Disciples, Co-Host of Legal Hackers Zurich, and a permanent member of expert groups at economiesuisse, the Swiss Fund and Asset Management Association and the Swiss Fintech Innovation Association.

Sabinije von Gaffke is a highly experienced, esteemed and awarded international Moderator, Facilitator, Speaker, Broadcast Journalist and Communications Catalyst in the intersection of Tech, Leadership, Sustainability, Impact and Health. She has extensive experience of global summits, digital summits, virtual meetings, live studio broadcasts, public speaking and leadership workshops.

Sabinije von Gaffke uses her expertise to engage people, companies and organisations seeking to improve cross-silo synergy and align internal and external stakeholders and implement purpose-driven strategies and leadership, through workshops, leadership retreats and public speaking facilitation.

As Editor-in-Chief of Longevity.Technology Phil oversees daily news and market research to address the crossover between longevity science and investment. This news platform has fast become the #1 for daily news and insights.

As founder of First Longevity Phil and his team help to prepare longevity science and technology businesses for equity funding ahead of introducing deals to, and syndicating deals among, VCs, family offices, and HNWs.

Prior to focusing exclusively on longevity, Phil has applied his marketing and business development expertise at c-level into: IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability markets.

Stephanie Dainow is Executive Director at Lifespan.io [Lifespan Extension Advocacy Foundation], a US based non-profit accelerating biomedical technologies that will increase healthy human lifespan through responsible journalism, research funding, advocacy, education and decentralizing aging research. She is also a Business Mentor to SOSV’s IndieBio venture fund and accelerator, consulting deep tech startup founders on business development and strategy, fundraising and executive leadership.

Previously, Stephanie was with Singularity University in Silicon Valley working across their Innovation Consultancy, Tech Think Tank, University for the Future, and Impact-based Startup Incubator. She also worked for a global management consultancy as a Life Sciences Business Manager and served as Account Director for BioMarin Pharmaceutical. Her early career in NYC spanned global growth for Interpublic Group’s media arm, celebrity and brand marketing, and commercial entertainment.

Stephanie has volunteered around the world and previously held an Advisory Board position at a 501c3 that inspires Harlem youth to pursue STEM careers. She is passionate about empowering leaders to think differently about emerging technologies, disruption, and the future of corporate business.

Ravi Jain began his education at the University of California, Davis, and received his PhD in bioinformatics from University of California, Los Angeles. He started his career designing drugs at Ionis Pharmaceuticals, an antisense drug development company, where his efforts received 12 patents.

Ravi has a background in microbial bioinformatics and was the co-founder and President of cBio, a bioinformatics/software development consulting firm. Under his leadership, cBio was awarded ‘Top-50 San Jose Business Journal’s Fastest Growing Private Company’ in 2010, 2011 & 2012.

Other experience includes serving as Managing Director of the UC Santa Cruz Genomics Institute. He then served as CSO of Hemostemix, where he ran a Phase II trial on stem cell therapeutics for vascular diseases. He concurrently serves as CEO of Domina Therapeutics, a spin-out of Dr. Evan Snyder’s SRF-supported work.

Tom has 35 years of senior management experience, primarily in the medical device industry, both early stage and public companies. He is a well-known entrepreneur and venture capitalist and holds nearly two dozen patents. He has founded over a dozen companies, which in total have created over $2 billion in shareholder value. He was also the co-founder and Chairman of a top quartile venture fund, Accuitive Medical Ventures, which raised a total of $230 million across two funds, and is now fully invested. Tom is the Founder, Chairman and CEO of Ponce de Leon Health (PDLH), a company with a mission to extend the length and quality of human life. PDLH is the world leading longevity company, and the only company to have demonstrated both safety and efficacy in humans with its product. The company has launched Rejuvant, a once-a-day pill shown to reduce biologic age, as measured by DNA methylation testing.